Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics

Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2019-06, Vol.59 (6), p.856-862
Hauptverfasser: Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Anderson, Jaclyn, Marbury, Thomas C., Othman, Ahmed A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 862
container_issue 6
container_start_page 856
container_title Journal of clinical pharmacology
container_volume 59
creator Mohamed, Mohamed‐Eslam F.
Trueman, Sheryl
Feng, Tian
Anderson, Jaclyn
Marbury, Thomas C.
Othman, Ahmed A.
description Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects with renal impairment. A total of 24 subjects between the ages of 18 and 75 years were assigned to 1 of 4 renal function groups based on estimated glomerular filtration rate (normal, mild, moderate, severe; N = 6/group). A single 15‐mg dose of upadacitinib extended‐release formulation was administered under fasting conditions. Serial plasma and urine samples were assayed to evaluate the effect of renal impairment on upadacitinib exposure through regression analysis and analysis of covariance. The primary analysis was the regression analysis of upadacitinib exposures versus estimated glomerular filtration rate. The point estimates for upadacitinib plasma exposure ratios (90% confidence interval [CI]) in subjects with mild, moderate, and severe renal impairment were 1.18 (90%CI, 1.06–1.32), 1.33 (90%CI, 1.11–1.59), and 1.44 (90%CI, 1.14–1.82) for area under the plasma concentration–time curve and 1.06 (90%CI, 0.92–1.23), 1.11 (90%CI, 0.88–1.40), and 1.14 (90%CI, 0.84–1.56) for maximum observed plasma concentration, respectively, relative to subjects with normal renal function based on the regression analysis. The analysis of covariance categorical analysis provided consistent results. Upadacitinib was well tolerated by all subjects, and no safety issues were identified in subjects with renal impairment. Renal impairment has a limited effect on upadacitinib pharmacokinetics. This is in agreement with the known limited role of urinary excretion in upadacitinib elimination. Based on the limited impact on exposure, no dose adjustment is necessary for upadacitinib in subjects with impaired renal function.
doi_str_mv 10.1002/jcph.1375
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6590375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2218841216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4815-564e1a717c41f8cc9aa67fb1f28bc9b4d12eee36e54ff229e9a1eb87e4f144273</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhi0EokvbAy-AInHqIa3HcZzkgoRWhRZVoqLt2Zp4x8TbJA52lqo8PV52qUCCk2XP529mfsZeAz8FzsXZ2kzdKRRV-YwtoCxFLhWXz9mC8wZyUXF-wF7FuOYclCzhJTsouCqKQjULdrPsMKCZKbgfODs_Zt5mc0fZubVk5u3tC43YZ5fDhC4MNKa3MbubcIXGzW50bXadFAMaf-9Gmp2JR-yFxT7S8f48ZHcfzm-XF_nV54-Xy_dXuZE1lHmpJAFWUBkJtjamQVSVbcGKujVNK1cgiKhQVEprhWioQaC2rkhakFJUxSF7t_NOm3aglUmzBez1FNyA4VF7dPrvyug6_dV_16pseEorCd7uBcF_21Cc9dpvQto2aiGgriUIUIk62VEm-BgD2acOwPU2f73NX8PO-ObPkZ7I34EnIN8BD75Pocf7fvNAQXeE_dz9U3i2511Pj__vrD8try9-_fgJYLehDQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2218841216</pqid></control><display><type>article</type><title>Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics</title><source>Wiley Journals</source><creator>Mohamed, Mohamed‐Eslam F. ; Trueman, Sheryl ; Feng, Tian ; Anderson, Jaclyn ; Marbury, Thomas C. ; Othman, Ahmed A.</creator><creatorcontrib>Mohamed, Mohamed‐Eslam F. ; Trueman, Sheryl ; Feng, Tian ; Anderson, Jaclyn ; Marbury, Thomas C. ; Othman, Ahmed A.</creatorcontrib><description>Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects with renal impairment. A total of 24 subjects between the ages of 18 and 75 years were assigned to 1 of 4 renal function groups based on estimated glomerular filtration rate (normal, mild, moderate, severe; N = 6/group). A single 15‐mg dose of upadacitinib extended‐release formulation was administered under fasting conditions. Serial plasma and urine samples were assayed to evaluate the effect of renal impairment on upadacitinib exposure through regression analysis and analysis of covariance. The primary analysis was the regression analysis of upadacitinib exposures versus estimated glomerular filtration rate. The point estimates for upadacitinib plasma exposure ratios (90% confidence interval [CI]) in subjects with mild, moderate, and severe renal impairment were 1.18 (90%CI, 1.06–1.32), 1.33 (90%CI, 1.11–1.59), and 1.44 (90%CI, 1.14–1.82) for area under the plasma concentration–time curve and 1.06 (90%CI, 0.92–1.23), 1.11 (90%CI, 0.88–1.40), and 1.14 (90%CI, 0.84–1.56) for maximum observed plasma concentration, respectively, relative to subjects with normal renal function based on the regression analysis. The analysis of covariance categorical analysis provided consistent results. Upadacitinib was well tolerated by all subjects, and no safety issues were identified in subjects with renal impairment. Renal impairment has a limited effect on upadacitinib pharmacokinetics. This is in agreement with the known limited role of urinary excretion in upadacitinib elimination. Based on the limited impact on exposure, no dose adjustment is necessary for upadacitinib in subjects with impaired renal function.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/jcph.1375</identifier><identifier>PMID: 30633369</identifier><language>eng</language><publisher>England: American College of Clinical Pharmacology</publisher><subject>Autoimmune diseases ; Enzyme inhibitors ; Excretion ; Exposure ; Glomerular filtration rate ; Impairment ; Janus kinase ; Janus kinase inhibitor ; Medical treatment ; Pharmacokinetics ; Plasma ; Regression analysis ; Renal function ; renal impairment ; Rheumatoid arthritis ; Special Populations ; upadacitinib ; Urine</subject><ispartof>Journal of clinical pharmacology, 2019-06, Vol.59 (6), p.856-862</ispartof><rights>2019, The Authors. published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology</rights><rights>2019 American College of Clinical Pharmacology</rights><rights>2019, The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.</rights><rights>2019, The American College of Clinical Pharmacology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4815-564e1a717c41f8cc9aa67fb1f28bc9b4d12eee36e54ff229e9a1eb87e4f144273</citedby><cites>FETCH-LOGICAL-c4815-564e1a717c41f8cc9aa67fb1f28bc9b4d12eee36e54ff229e9a1eb87e4f144273</cites><orcidid>0000-0002-4937-2775</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcph.1375$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcph.1375$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30633369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohamed, Mohamed‐Eslam F.</creatorcontrib><creatorcontrib>Trueman, Sheryl</creatorcontrib><creatorcontrib>Feng, Tian</creatorcontrib><creatorcontrib>Anderson, Jaclyn</creatorcontrib><creatorcontrib>Marbury, Thomas C.</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><title>Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects with renal impairment. A total of 24 subjects between the ages of 18 and 75 years were assigned to 1 of 4 renal function groups based on estimated glomerular filtration rate (normal, mild, moderate, severe; N = 6/group). A single 15‐mg dose of upadacitinib extended‐release formulation was administered under fasting conditions. Serial plasma and urine samples were assayed to evaluate the effect of renal impairment on upadacitinib exposure through regression analysis and analysis of covariance. The primary analysis was the regression analysis of upadacitinib exposures versus estimated glomerular filtration rate. The point estimates for upadacitinib plasma exposure ratios (90% confidence interval [CI]) in subjects with mild, moderate, and severe renal impairment were 1.18 (90%CI, 1.06–1.32), 1.33 (90%CI, 1.11–1.59), and 1.44 (90%CI, 1.14–1.82) for area under the plasma concentration–time curve and 1.06 (90%CI, 0.92–1.23), 1.11 (90%CI, 0.88–1.40), and 1.14 (90%CI, 0.84–1.56) for maximum observed plasma concentration, respectively, relative to subjects with normal renal function based on the regression analysis. The analysis of covariance categorical analysis provided consistent results. Upadacitinib was well tolerated by all subjects, and no safety issues were identified in subjects with renal impairment. Renal impairment has a limited effect on upadacitinib pharmacokinetics. This is in agreement with the known limited role of urinary excretion in upadacitinib elimination. Based on the limited impact on exposure, no dose adjustment is necessary for upadacitinib in subjects with impaired renal function.</description><subject>Autoimmune diseases</subject><subject>Enzyme inhibitors</subject><subject>Excretion</subject><subject>Exposure</subject><subject>Glomerular filtration rate</subject><subject>Impairment</subject><subject>Janus kinase</subject><subject>Janus kinase inhibitor</subject><subject>Medical treatment</subject><subject>Pharmacokinetics</subject><subject>Plasma</subject><subject>Regression analysis</subject><subject>Renal function</subject><subject>renal impairment</subject><subject>Rheumatoid arthritis</subject><subject>Special Populations</subject><subject>upadacitinib</subject><subject>Urine</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kMFu1DAQhi0EokvbAy-AInHqIa3HcZzkgoRWhRZVoqLt2Zp4x8TbJA52lqo8PV52qUCCk2XP529mfsZeAz8FzsXZ2kzdKRRV-YwtoCxFLhWXz9mC8wZyUXF-wF7FuOYclCzhJTsouCqKQjULdrPsMKCZKbgfODs_Zt5mc0fZubVk5u3tC43YZ5fDhC4MNKa3MbubcIXGzW50bXadFAMaf-9Gmp2JR-yFxT7S8f48ZHcfzm-XF_nV54-Xy_dXuZE1lHmpJAFWUBkJtjamQVSVbcGKujVNK1cgiKhQVEprhWioQaC2rkhakFJUxSF7t_NOm3aglUmzBez1FNyA4VF7dPrvyug6_dV_16pseEorCd7uBcF_21Cc9dpvQto2aiGgriUIUIk62VEm-BgD2acOwPU2f73NX8PO-ObPkZ7I34EnIN8BD75Pocf7fvNAQXeE_dz9U3i2511Pj__vrD8try9-_fgJYLehDQ</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Mohamed, Mohamed‐Eslam F.</creator><creator>Trueman, Sheryl</creator><creator>Feng, Tian</creator><creator>Anderson, Jaclyn</creator><creator>Marbury, Thomas C.</creator><creator>Othman, Ahmed A.</creator><general>American College of Clinical Pharmacology</general><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4937-2775</orcidid></search><sort><creationdate>201906</creationdate><title>Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics</title><author>Mohamed, Mohamed‐Eslam F. ; Trueman, Sheryl ; Feng, Tian ; Anderson, Jaclyn ; Marbury, Thomas C. ; Othman, Ahmed A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4815-564e1a717c41f8cc9aa67fb1f28bc9b4d12eee36e54ff229e9a1eb87e4f144273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Autoimmune diseases</topic><topic>Enzyme inhibitors</topic><topic>Excretion</topic><topic>Exposure</topic><topic>Glomerular filtration rate</topic><topic>Impairment</topic><topic>Janus kinase</topic><topic>Janus kinase inhibitor</topic><topic>Medical treatment</topic><topic>Pharmacokinetics</topic><topic>Plasma</topic><topic>Regression analysis</topic><topic>Renal function</topic><topic>renal impairment</topic><topic>Rheumatoid arthritis</topic><topic>Special Populations</topic><topic>upadacitinib</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohamed, Mohamed‐Eslam F.</creatorcontrib><creatorcontrib>Trueman, Sheryl</creatorcontrib><creatorcontrib>Feng, Tian</creatorcontrib><creatorcontrib>Anderson, Jaclyn</creatorcontrib><creatorcontrib>Marbury, Thomas C.</creatorcontrib><creatorcontrib>Othman, Ahmed A.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohamed, Mohamed‐Eslam F.</au><au>Trueman, Sheryl</au><au>Feng, Tian</au><au>Anderson, Jaclyn</au><au>Marbury, Thomas C.</au><au>Othman, Ahmed A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>59</volume><issue>6</issue><spage>856</spage><epage>862</epage><pages>856-862</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases. The objective of this study was to assess the pharmacokinetics and safety of a single upadacitinib dose in subjects with normal renal function and in subjects with renal impairment. A total of 24 subjects between the ages of 18 and 75 years were assigned to 1 of 4 renal function groups based on estimated glomerular filtration rate (normal, mild, moderate, severe; N = 6/group). A single 15‐mg dose of upadacitinib extended‐release formulation was administered under fasting conditions. Serial plasma and urine samples were assayed to evaluate the effect of renal impairment on upadacitinib exposure through regression analysis and analysis of covariance. The primary analysis was the regression analysis of upadacitinib exposures versus estimated glomerular filtration rate. The point estimates for upadacitinib plasma exposure ratios (90% confidence interval [CI]) in subjects with mild, moderate, and severe renal impairment were 1.18 (90%CI, 1.06–1.32), 1.33 (90%CI, 1.11–1.59), and 1.44 (90%CI, 1.14–1.82) for area under the plasma concentration–time curve and 1.06 (90%CI, 0.92–1.23), 1.11 (90%CI, 0.88–1.40), and 1.14 (90%CI, 0.84–1.56) for maximum observed plasma concentration, respectively, relative to subjects with normal renal function based on the regression analysis. The analysis of covariance categorical analysis provided consistent results. Upadacitinib was well tolerated by all subjects, and no safety issues were identified in subjects with renal impairment. Renal impairment has a limited effect on upadacitinib pharmacokinetics. This is in agreement with the known limited role of urinary excretion in upadacitinib elimination. Based on the limited impact on exposure, no dose adjustment is necessary for upadacitinib in subjects with impaired renal function.</abstract><cop>England</cop><pub>American College of Clinical Pharmacology</pub><pmid>30633369</pmid><doi>10.1002/jcph.1375</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4937-2775</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2019-06, Vol.59 (6), p.856-862
issn 0091-2700
1552-4604
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6590375
source Wiley Journals
subjects Autoimmune diseases
Enzyme inhibitors
Excretion
Exposure
Glomerular filtration rate
Impairment
Janus kinase
Janus kinase inhibitor
Medical treatment
Pharmacokinetics
Plasma
Regression analysis
Renal function
renal impairment
Rheumatoid arthritis
Special Populations
upadacitinib
Urine
title Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20Effect%20of%20Renal%20Impairment%20on%20Upadacitinib%20Pharmacokinetics&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Mohamed,%20Mohamed%E2%80%90Eslam%20F.&rft.date=2019-06&rft.volume=59&rft.issue=6&rft.spage=856&rft.epage=862&rft.pages=856-862&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1002/jcph.1375&rft_dat=%3Cproquest_pubme%3E2218841216%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2218841216&rft_id=info:pmid/30633369&rfr_iscdi=true